Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by the loss or low expression of estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2) and progesterone receptor (PR). Due to the lack of clear therapeutic targets, paclitaxel (PTX)...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006424004198 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846123334229557248 |
|---|---|
| author | Jia-xin Qiao Dong-yan Guo Huan Tian Zhan-peng Wang Qiang-qiang Fan Yuan Tian Jing Sun Xiao-fei Zhang Jun-bo Zou Jiang-xue Cheng Fei Luan Bing-tao Zhai |
| author_facet | Jia-xin Qiao Dong-yan Guo Huan Tian Zhan-peng Wang Qiang-qiang Fan Yuan Tian Jing Sun Xiao-fei Zhang Jun-bo Zou Jiang-xue Cheng Fei Luan Bing-tao Zhai |
| author_sort | Jia-xin Qiao |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by the loss or low expression of estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2) and progesterone receptor (PR). Due to the lack of clear therapeutic targets, paclitaxel (PTX) is often used as a first-line standard chemotherapy drug for the treatment of high-risk and locally advanced TNBC. PTX is a diterpenoid alkaloid extracted and purified from Taxus plants, functioning as an anticancer agent by inducing and promoting tubulin polymerization, inhibiting spindle formation in cancer cells, and preventing mitosis. However, its clinical application is limited by low solubility and high toxicity. Nanodrug delivery system (NDDS) is one of the feasible methods to improve the water solubility of PTX and reduce side effects. In this review, we summarize the latest advancements in PTX-targeted NDDS, as well as its combination with other codelivery therapies for TNBC treatment. NDDS includes passive targeting, active targeting, stimuli-responsive, codelivery, and multimode strategies. These systems have good prospects in improving the bioavailability of PTX, enhancing tumor targeting, reducing toxicity, controlling drug release, and reverse tumor multidrug resistance (MDR). This review provides valuable insights into the clinical development and application of PTX-targeted NDDS in the treatment of TNBC. |
| format | Article |
| id | doaj-art-511858e1b9ea40b5bd56c51bde34cad7 |
| institution | Kabale University |
| issn | 2590-0064 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj-art-511858e1b9ea40b5bd56c51bde34cad72024-12-14T06:32:25ZengElsevierMaterials Today Bio2590-00642024-12-0129101358Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancerJia-xin Qiao0Dong-yan Guo1Huan Tian2Zhan-peng Wang3Qiang-qiang Fan4Yuan Tian5Jing Sun6Xiao-fei Zhang7Jun-bo Zou8Jiang-xue Cheng9Fei Luan10Bing-tao Zhai11State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, ChinaState Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, ChinaDepartment of Pharmacy, National Old Pharmacist Inheritance Studio, Xi'an Hospital of Traditional Chinese Medicine, Xi'an, 710021, ChinaState Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, ChinaState Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, ChinaState Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, ChinaState Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, ChinaState Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, ChinaState Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, ChinaState Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, ChinaState Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, ChinaState Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, China; Corresponding author.Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by the loss or low expression of estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2) and progesterone receptor (PR). Due to the lack of clear therapeutic targets, paclitaxel (PTX) is often used as a first-line standard chemotherapy drug for the treatment of high-risk and locally advanced TNBC. PTX is a diterpenoid alkaloid extracted and purified from Taxus plants, functioning as an anticancer agent by inducing and promoting tubulin polymerization, inhibiting spindle formation in cancer cells, and preventing mitosis. However, its clinical application is limited by low solubility and high toxicity. Nanodrug delivery system (NDDS) is one of the feasible methods to improve the water solubility of PTX and reduce side effects. In this review, we summarize the latest advancements in PTX-targeted NDDS, as well as its combination with other codelivery therapies for TNBC treatment. NDDS includes passive targeting, active targeting, stimuli-responsive, codelivery, and multimode strategies. These systems have good prospects in improving the bioavailability of PTX, enhancing tumor targeting, reducing toxicity, controlling drug release, and reverse tumor multidrug resistance (MDR). This review provides valuable insights into the clinical development and application of PTX-targeted NDDS in the treatment of TNBC.http://www.sciencedirect.com/science/article/pii/S2590006424004198PaclitaxelTriple-negative breast cancerNDDSCodeliveryMultimode strategy |
| spellingShingle | Jia-xin Qiao Dong-yan Guo Huan Tian Zhan-peng Wang Qiang-qiang Fan Yuan Tian Jing Sun Xiao-fei Zhang Jun-bo Zou Jiang-xue Cheng Fei Luan Bing-tao Zhai Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer Materials Today Bio Paclitaxel Triple-negative breast cancer NDDS Codelivery Multimode strategy |
| title | Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer |
| title_full | Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer |
| title_fullStr | Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer |
| title_full_unstemmed | Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer |
| title_short | Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer |
| title_sort | research progress of paclitaxel nanodrug delivery system in the treatment of triple negative breast cancer |
| topic | Paclitaxel Triple-negative breast cancer NDDS Codelivery Multimode strategy |
| url | http://www.sciencedirect.com/science/article/pii/S2590006424004198 |
| work_keys_str_mv | AT jiaxinqiao researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT dongyanguo researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT huantian researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT zhanpengwang researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT qiangqiangfan researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT yuantian researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT jingsun researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT xiaofeizhang researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT junbozou researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT jiangxuecheng researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT feiluan researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer AT bingtaozhai researchprogressofpaclitaxelnanodrugdeliverysysteminthetreatmentoftriplenegativebreastcancer |